KeithEStockerl-GoldsteinMD

Oncology • Saint Louis, MO

Hematologic Oncology

Professor of Medicine BMT/Leukemia Program

Join to view full profile

Dr. Stockerl-Goldstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Stockerl-Goldstein's full profile

Already have an account?

Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110
Phone+1 314-454-8304

Fax+1 314-454-5902

Summary

Dr. Keith Stockerl-Goldstein is an oncologist in Saint Louis, MO and is affiliated with multiple hospitals in the area, including Barnes-Jewish Hospital and Siteman Cancer Center. He received his medical degree from David Geffen School of Medicine at UCLA and has been in practice 26 years. He specializes in hematologic oncology and is experienced in hematologic oncology, hematopoietic stem cell transplantation, multiple myeloma, amyloidosis, leukemia, and transplantation conditioning.
He currently serves as an Associate Program Director for the Hematology /Oncology Fellowship Program.

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1993 - 1996
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1991 - 1993
David Geffen School of Medicine at UCLAClass of 1991

Certifications & Licensure

IL State Medical License 2020 - 2026
MO State Medical License 2007 - 2025
CA State Medical License 1993 - 2007
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Mixed Chimeric Transplantation for Primary Amyloidosis Start of enrollment: 2000 Dec 01
Withdrawn
Not Applicable
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2009 May 05
Active, not recruiting
Phase 2
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia Start of enrollment: 2011 Feb 01
Completed
Phase 1, Phase 2
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2012 May 14
Completed
Phase 1, Phase 2
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation Start of enrollment: 2013 Feb 25
Completed
Phase 1
Geriatric Assessments in Senior Adults With Multiple Myeloma Start of enrollment: 2012 Sep 01
Completed
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation Start of enrollment: 2013 Apr 15
Terminated
Phase 1, Phase 2
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Aug 11
Terminated
Phase 1, Phase 2
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19
Completed
Phase 2
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Feb 28
Terminated
Phase 1
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Start of enrollment: 2014 Aug 20
Completed
Phase 2
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation Start of enrollment: 2015 Jan 20
Terminated
Phase 2
Falls Risk Questionnaire in Older Adults With Cancer Start of enrollment: 2014 Aug 01
Completed
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Start of enrollment: 2015 Feb 20
Completed
Phase 1
Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) Start of enrollment: 2021 May 05
Completed
Phase 2
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease Start of enrollment: 2022 Apr 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

1214 citations
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein
Lancet. 2020-06-20
81 citations
Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience
Antonio C. Wolff, Amanda L. Blackford, Kala Visvanathan, Hope S. Rugo, Beverly Moy
Journal of Clinical Oncology. 2015-02-01
583 citations
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
John S. Welch, Allegra A. Petti, Christopher A. Miller, Catrina Fronick, Michelle O'Laughlin
The New England Journal of Medicine. 2016-11-23

Abstracts/Posters

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
Keith E. Stockerl-Goldstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Ire of IRE1_: Overexpression of IRE1_ at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1_ Expression Is Predictive of Therapy ...
Keith E. Stockerl-Goldstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

D.C.E.P. in Patients with Quad- or Penta-Refractory Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

GlycoMimetics Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan for Prevention of Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell TransplantationMay 26th, 2021
Drug Combination Shows Promise for Newly Diagnosed Blood Cancer Patients, Study FindsDecember 11th, 2010